Shortages, access, and cost have led to compounding GLP1s, which has created confusion and misinformation for patients and healthcare providers. Join us as we discuss this practice and delve into what you need to know as a healthcare provider.

THE GAMECHANGER: The advent of GLP1s is a true GameChanger in the health of patients with diabetes, cardiovascular diseases, and obesity, and has led to access issues for manufactured products.

Upon successful completion of this course, learners should be able to:
1. Review criteria for compounding drugs on the FDA drug shortage list.
2. Discuss the facts and misinformation surrounding compounded GLP1 medications.

Guests:

Tenille Davis, PharmD, RPh
Chief Advocacy Officer
Alliance for Pharmacy Compounding

Scott Brunner, CAE
CEO
Alliance for Pharmacy Compounding

Dr. Davis has no relevant financial relationships with ineligible companied to disclose.
Dr. Brunner has no relevant financial relationships with ineligible companied to disclose.

Host
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: April 15, 2024
Planned Expiration Date: April 15, 2025

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.